We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of eye, brain and other parts of central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Glioblastoma is the most common brain tumour in adults associated with a high symptom burden and poor prognosis. Currently,patients with glioblastoma undergo imaging at set time points,known as surveillance imaging,to look for tumour growth and check whether tumours are responding to treatment. Yet,it is not known whether scanning at these specific times changes patient outcomes such as survival. In addition,frequent imaging and uncertainty regarding tumour recurrence can cause unnecessary anxiety and increase in symptom severity,which can negatively affect a patients’ quality of life (QoL).
In this feasibility study,we propose an alternative approach,which is looking into triggered imaging based on patient reported outcome (PRO) and performance-based outcome (PerfO) measures. PROs are directly reported by the patient and reflects their own perception of symptoms and function associated with the disease or treatment. There are indications PROs can contribute to improved survival and maintaining an optimal quality of life in other oncology populations. PerfO measures in contrast,are usually administered by a health care professional and performed by the patient,Eligible patients will be recruited from neuro-oncology clinics and randomized into an intervention and control group. Patients in the intervention arm will be invited to complete weekly online symptom questionnaires as well as undertake monthly cognition tests. Self-reporting of severe or worsening symptoms which meet pre-defined threshold criteria,as well as decline in cognitive function,will trigger notification alerts to the research and clinical team,who will be able to expedite a fast track MRI.
This comprehensive approach of active symptom monitoring and cognitive testing can provide a better picture of overall disease status and functional ability,facilitating the development of patient reported and machine learning biomarkers with potential to inform future imaging guidelines and practices.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Imaging;
You can take part if:
You may not be able to take part if:
i. Uncertainty of diagnosis ii. Deviation from the standard Stupp regimen iii. Patients participating in another interventional study iv. Unable to read and comprehend English language text v. Lack capacity at point of consent vi. WHO Performance status > 3 (Karnofsky score < 30)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by BRITISH SOCIETY OF NEURORADIOLOGISTS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 61204
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
